Dissemination of 2014 dual antiplatelet therapy (DAPT) trial results: a systematic review of scholarly and media attention over 7 months
Open accessThe DOI matches its Crossref record; 30 of the 32 references it cites were found in a registry or an index.
Abstract
Objective: To explore how the results from the 2014 dual antiplatelet therapy (DAPT) trial were disseminated to the scientific community and online media. Design: A a systematic review of scholarly and public attention surrounding the DAPT study. Settings: Data were collected from the ISI Web of Knowledge, Google Scholar, PubMed Commons, EurekAlert, the DAPT study website ( www.daptstudy.org ) and the New England Journal of Medicine website (for scholarly attention) and Altmetric Explorer, Snap Bird, YouTube (for public attention) citing DAPT study results appearing from 16 November 2014 to 10 June 2015. Participants: No participants were involved in this study. Main outcome measure: Proportion of contents highlighting the increased risk of mortality and critical to the author’s interpretation of the results. Results: We identified 425 items reported by seven sources; 164 (39%) disseminated the authors’ interpretation via an electronic link or a reference, with no additional text. Among 81 items (19 %), the message favoured prolonged treatment and consequently overstated the article conclusions. Among 119 items (28 %), the text was uncertain about the benefit of prolonged treatment but was reported with no or inappropriate mention of increased risk of mortality. Only 34 items (8 %) were uncertain about the benefit of prolonged treatment and mentioned increased risk of mortality. In all, 27 items (6 %) did not favour prolonged treatment, and only 12 of these (3 %) clearly raised some concerns about the reporting of increased risk of death. Conclusion: Dissemination of the DAPT study results to the scientific community and on different media sources rarely criticised the interpretation of the study results.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“For example, the reporting and interpretation of the risk of all-cause mortality in the DAPT (dual antiplatelet therapy) study randomizing 9,961 patients to continue DAPT beyond 1 y after stent placement or receive a placebo for 30 mo, raised some concerns (24, 25).”
From Misrepresentation and distortion of research in biomedical literature (2018) · cites this paper as [25]
The cited source says what the claim attributes to it.
In the citing paper
“For example, in the DAPT study, the authors proposed a post hoc explanation for the increased rate of death in the experimental group based on a post hoc analysis to mitigate the role of prolonged treatment on this increased risk of mortality (25).”
From Misrepresentation and distortion of research in biomedical literature (2018) · cites this paper as [25]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Heart Disease and Stroke Statistics—2015 Update: A Report From the American Heart Association
Mozaffarian, D., Benjamin, E. J., Go, A. S., Arnett, D. K., Blaha, M. J., Cushman, M., de Ferranti, S., Després, J.-P., Fullerton, H. J., Howard, V. J., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000152 · Cited by 5,797
(2014) · European Heart Journal · doi:10.1093/eurheartj/ehu278 · Cited by 4,314
2014 ESC/EACTS Guidelines on myocardial revascularization
Kolh, P., Windecker, S., Alfonso, F., Collet, J.-P., Cremer, J., Falk, V., Filippatos, G., Hamm, C., Head, S. J., Jüni, P., et al. (2014) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezu366 · Cited by 4,199
Writing Committee Members, Levine, G. N., Bates, E. R., Blankenship, J. C., Bailey, S. R., Bittl, J. A., Cercek, B., Chambers, C. E., Ellis, S. G., Guyton, R. A., et al. (2011) · Circulation · doi:10.1161/cir.0b013e31823ba622 · Cited by 3,289
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention
Levine, G. N., Bates, E. R., Blankenship, J. C., Bailey, S. R., Bittl, J. A., Cercek, B., Chambers, C. E., Ellis, S. G., Guyton, R. A., Hollenberg, S. M., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.08.007 · Cited by 2,164
Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents
Mauri, L., Kereiakes, D. J., Yeh, R. W., Driscoll-Shempp, P., Cutlip, D. E., Steg, P. G., Normand, S.-L. T., Braunwald, E., Wiviott, S. D., Cohen, D. J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409312 · Cited by 1,928 · cited 4×
“The trial aimed to determine the benefits and risks of continuing DAPT beyond 1 year after placement of a coronary stent.(9) A total of 9961 adult patients were randomly assigned to continue thienopyridine treatment or to receive a placebo for 30 months.”
InfluentialChan, A.-W., Hróbjartsson, A., Haahr, M. T., Gøtzsche, P. C., & Altman, D. G. (2004) · JAMA · doi:10.1001/jama.291.20.2457 · Cited by 1,845
Systematic Review of the Empirical Evidence of Study Publication Bias and Outcome Reporting Bias
Dwan, K., Altman, D. G., Arnaiz, J. A., Bloom, J., Chan, A.-W., Cronin, E., Decullier, E., Easterbrook, P. J., Von Elm, E., Gamble, C., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003081 · Cited by 1,546
Eysenbach, G. (2011) · Journal of Medical Internet Research · doi:10.2196/jmir.2012 · Cited by 1,083
Do Altmetrics Work? Twitter and Ten Other Social Web Services
Thelwall, M., Haustein, S., Larivière, V., & Sugimoto, C. R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064841 · Cited by 907
Cited by
Misrepresentation and distortion of research in biomedical literature
Boutron, I., & Ravaud, P. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1710755115 · Cited by 273
Self-citationSharp, M. K. (2020) · theses.fr (ABES) · doi:10.70675/8b04d8e9zf7e8z40c8za3dcz036c51a4b547 · Cited by 3
Self-citation
Metadata
- Authors
- Sharp, M. K., Haneef, R., Ravaud, P., & Boutron, I.
- Affiliations
- Inserm (FR)
- Corresponding author
- Boutron, Isabelle
- Venue
- BMJ Open
- Publisher
- BMJ
- Published
- 2017-11
- Volume
- 7
- Issue
- 11
- Pages
- e014503
- ISSN
- 2044-6055 (ISSN-L)
- PMC
- PMC5695450
- OpenAlex
- W2766796841
- Cited by
- 1
- References
- 32
- Citations by year
- 2018: 1
- FWCI
- 0.07
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- BMJ Open (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- European Commission (676207, HORIZON2020)
- Topics
- Social Sciences › Library and Information Sciences › Academic Publishing and Open Access
- Social Sciences › Decision Sciences › Statistics, Probability and Uncertainty › Meta-analysis and systematic reviews
- Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
- Keywords
- dual antiplatelet therapy, research dissemination, media coverage, scientific attention, mortality risk, risk communication
- MeSH terms
- Data Interpretation, Statistical, Humans, Platelet Aggregation Inhibitors, Randomized Controlled Trials as Topic, Information Dissemination, Social Media
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dissemination of 2014 dual antiplatelet therapy (DAPT) trial results: a systematic review of scholarly and media attention over 7 months. https://app.cochat.ai/papers/10.1136/bmjopen-2016-014503
- The paper
- Sharp, M. K., Haneef, R., Ravaud, P., & Boutron, I. (2017). Dissemination of 2014 dual antiplatelet therapy (DAPT) trial results: a systematic review of scholarly and media attention over 7 months. BMJ Open. https://doi.org/10.1136/bmjopen-2016-014503
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.